Management of concomitant hepatocellular carcinoma and chronic hepatitis C: a review

Elizabeth Harrod; Carlos Moctezuma-Velazquez; Ahmet Gurakar; Aftab Ala; Douglas Dieterich; Behnam Saberi

doi:10.20517/2394-5079.2019.15

Management of concomitant hepatocellular carcinoma and chronic hepatitis C: a review

Elizabeth Harrod, Carlos Moctezuma-Velazquez, Ahmet Gurakar, Aftab Ala, Douglas Dieterich, Behnam Saberi

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Our comprehensive review focuses on the treatment of hepatitis C virus in the context of hepatocellular carcinoma and vice versa, highlighting the ongoing complexity of this clinical scenario. There remain multiple unanswered questions when considering the management of these complex patients and, with a rapidly-changing treatment landscape for both chronic hepatitis C and hepatocellular carcinoma, these questions are only going to grow. Treatment timing, interactions and the impact of one disease condition on the other are vitally important, though guidance generally remains non-specific, suggesting that we make these decisions on a case-by-case basis. We focus on the current evidence for managing these cases, depending on disease stage and treatment type.

Original language	English
Article number	28
Journal	Hepatoma Research
Volume	5
DOIs	https://doi.org/10.20517/2394-5079.2019.15
State	Published - 2019

Keywords

Hepatocellular carcinoma
direct-acting antiviral agents
hepatitis C virus
liver cancer

Access to Document

10.20517/2394-5079.2019.15

Cite this

@article{6d2e06e8d1c6498e93436d2540e5c5a8,

title = "Management of concomitant hepatocellular carcinoma and chronic hepatitis C: a review",

abstract = "Our comprehensive review focuses on the treatment of hepatitis C virus in the context of hepatocellular carcinoma and vice versa, highlighting the ongoing complexity of this clinical scenario. There remain multiple unanswered questions when considering the management of these complex patients and, with a rapidly-changing treatment landscape for both chronic hepatitis C and hepatocellular carcinoma, these questions are only going to grow. Treatment timing, interactions and the impact of one disease condition on the other are vitally important, though guidance generally remains non-specific, suggesting that we make these decisions on a case-by-case basis. We focus on the current evidence for managing these cases, depending on disease stage and treatment type.",

keywords = "Hepatocellular carcinoma, direct-acting antiviral agents, hepatitis C virus, liver cancer",

author = "Elizabeth Harrod and Carlos Moctezuma-Velazquez and Ahmet Gurakar and Aftab Ala and Douglas Dieterich and Behnam Saberi",

note = "Funding Information: CMV is a recipient of a grant from Gilead, Canada. Publisher Copyright: {\textcopyright} The Author(s) 2019.",

year = "2019",

doi = "10.20517/2394-5079.2019.15",

language = "English",

volume = "5",

journal = "Hepatoma Research",

issn = "2394-5079",

publisher = "OAE Publishing Inc.",

}

TY - JOUR

T1 - Management of concomitant hepatocellular carcinoma and chronic hepatitis C

T2 - a review

AU - Harrod, Elizabeth

AU - Moctezuma-Velazquez, Carlos

AU - Gurakar, Ahmet

AU - Ala, Aftab

AU - Dieterich, Douglas

AU - Saberi, Behnam

N1 - Funding Information: CMV is a recipient of a grant from Gilead, Canada. Publisher Copyright: © The Author(s) 2019.

PY - 2019

Y1 - 2019

N2 - Our comprehensive review focuses on the treatment of hepatitis C virus in the context of hepatocellular carcinoma and vice versa, highlighting the ongoing complexity of this clinical scenario. There remain multiple unanswered questions when considering the management of these complex patients and, with a rapidly-changing treatment landscape for both chronic hepatitis C and hepatocellular carcinoma, these questions are only going to grow. Treatment timing, interactions and the impact of one disease condition on the other are vitally important, though guidance generally remains non-specific, suggesting that we make these decisions on a case-by-case basis. We focus on the current evidence for managing these cases, depending on disease stage and treatment type.

AB - Our comprehensive review focuses on the treatment of hepatitis C virus in the context of hepatocellular carcinoma and vice versa, highlighting the ongoing complexity of this clinical scenario. There remain multiple unanswered questions when considering the management of these complex patients and, with a rapidly-changing treatment landscape for both chronic hepatitis C and hepatocellular carcinoma, these questions are only going to grow. Treatment timing, interactions and the impact of one disease condition on the other are vitally important, though guidance generally remains non-specific, suggesting that we make these decisions on a case-by-case basis. We focus on the current evidence for managing these cases, depending on disease stage and treatment type.

KW - Hepatocellular carcinoma

KW - direct-acting antiviral agents

KW - hepatitis C virus

KW - liver cancer

UR - http://www.scopus.com/inward/record.url?scp=85087409457&partnerID=8YFLogxK

U2 - 10.20517/2394-5079.2019.15

DO - 10.20517/2394-5079.2019.15

M3 - Review article

AN - SCOPUS:85087409457

SN - 2394-5079

VL - 5

JO - Hepatoma Research

JF - Hepatoma Research

M1 - 28

ER -

Management of concomitant hepatocellular carcinoma and chronic hepatitis C: a review

Abstract

Keywords

Access to Document

Fingerprint

Cite this